Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan.
Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan.
Am J Cardiol. 2021 Nov 15;159:100-106. doi: 10.1016/j.amjcard.2021.08.023.
Current guidelines recommend targeting an international normalized ratio (INR) of 2.5 to 3.5 for patients with mechanical aortic valve replacement (AVR) and additional risk factors for thromboembolic events. Available literature supporting the higher intensity (INR) goal is lacking. We aimed to evaluate the association of standard and higher intensity anticoagulation on outcomes in this patient population. The Michigan Anticoagulation Quality Improvement Initiative database was used to identify patients with mechanical AVR and at least one additional risk factor. Patients were classified into 2 groups based on INR goal: standard-intensity (INR goal 2.5) or higher-intensity (INR goal 3.0). Cox-proportional hazard model was used to calculate adjusted hazard ratios. One hundred and forty-six patients were identified of whom 110 (75.3%) received standard-intensity anticoagulation and 36 (24.7%) received higher intensity anticoagulation. Standard-intensity patients were older and more likely to be on aspirin. Atrial fibrillation was the most common additional risk factor for inclusion. The primary outcome of thromboembolic events, bleeding, or all-cause death was 13.9 and 19.5/100-person-years in the standard-intensity and higher intensity groups, respectively (adjusted HR 2.58, 95% confidence interval 1.28 to 5.18). Higher-intensity anticoagulation was significantly associated with any bleeding (adjusted HR 2.52, 95% confidence interval 1.27 to 5.00) and there were few thromboembolic events across both groups (5 events total). These results challenge current guideline recommendations for anticoagulation management of mechanical AVR in patients with additional risk factors.
目前的指南建议,对于接受机械主动脉瓣置换术(AVR)且存在血栓栓塞事件额外风险因素的患者,目标国际标准化比值(INR)为 2.5 至 3.5。缺乏支持更高强度(INR)目标的现有文献。我们旨在评估标准强度和更高强度抗凝治疗在该患者人群中的疗效关联。我们使用密歇根抗凝质量改进倡议数据库来识别接受机械 AVR 且至少存在一个额外风险因素的患者。根据 INR 目标将患者分为 2 组:标准强度(INR 目标 2.5)或更高强度(INR 目标 3.0)。使用 Cox 比例风险模型计算调整后的危险比。确定了 146 名患者,其中 110 名(75.3%)接受标准强度抗凝治疗,36 名(24.7%)接受更高强度抗凝治疗。标准强度患者年龄较大,更有可能服用阿司匹林。房颤是纳入的最常见的额外风险因素。血栓栓塞事件、出血或全因死亡的主要结局分别为标准强度组和更高强度组的 13.9 和 19.5/100 人年(调整后的 HR 2.58,95%置信区间 1.28 至 5.18)。更高强度抗凝治疗与任何出血显著相关(调整后的 HR 2.52,95%置信区间 1.27 至 5.00),且两组的血栓栓塞事件均较少(总共有 5 例)。这些结果对当前指南建议的存在额外风险因素的机械 AVR 患者抗凝管理提出了挑战。